Skip to main content

Lichter Jay's Form 4 filing

Janux Therapeutics, Inc. (JANX) · filed Sep 12, 2024

Accession no.
0001415889-24-023337
Filed
Sep 12, 2024, 8:42 PM ET
Trade date
Sep 10-12, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market sales total $21.2M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lichter JayCIK 000137635510% Owner
Avalon Ventures XI, L.P.CIK 000165290110% Owner
Avalon BioVentures SPV I, L.P.CIK 000184455010% Owner
Avalon BioVentures I, LPCIK 000187393510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 10, 2024Common StockSSaleDisposed−11,319$46.13−$522,145.473,151,532Direct
Sep 10, 2024Common StockSSaleDisposed−2,193$46.13−$101,163.09610,489Indirect
Sep 10, 2024Common StockSSaleDisposed−11,557$46.13−$533,124.413,217,817Indirect
Sep 10, 2024Common StockSSaleDisposed−34,326$46.66−$1,601,651.163,117,206Direct
Sep 10, 2024Common StockSSaleDisposed−6,649$46.66−$310,242.34603,840Indirect
Sep 10, 2024Common StockSSaleDisposed−35,047$46.66−$1,635,293.023,182,770Indirect
Sep 12, 2024Common StockSSaleDisposed−158,031$47.00−$7,427,4572,959,175Direct
Sep 12, 2024Common StockSSaleDisposed−30,613$47.00−$1,438,811573,227Indirect
Sep 12, 2024Common StockSSaleDisposed−161,356$47.00−$7,583,7323,021,414Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)